BAVARIAN NORDIC/S (BVNRY) to Release Earnings on Wednesday

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) is set to issue its quarterly earnings data before the market opens on Wednesday, May 22nd. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.

BVNRY stock opened at $6.64 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.84 and a current ratio of 6.15. BAVARIAN NORDIC/S has a 52 week low of $5.92 and a 52 week high of $10.78.

Separately, Zacks Investment Research lowered shares of BAVARIAN NORDIC/S from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th.

COPYRIGHT VIOLATION NOTICE: This report was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at


Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.

Recommended Story: Should You Consider an Index Fund?


Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with's FREE daily email newsletter.